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ABSTRACT: N-Myristoyltransferase (NMT) is an essential eukaryotic enzyme and an attractive drug target in parasitic
infections such as malaria. We have previously reported that 2-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimethyl-
1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c) is a high aﬃnity inhibitor of both Plasmodium falciparum and P. vivax NMT and
displays activity in vivo against a rodent malaria model. Here we describe the discovery of 34c through optimization of a
previously described series. Development, guided by targeting a ligand eﬃciency dependent lipophilicity (LELP) score of less
than 10, yielded a 100-fold increase in enzyme aﬃnity and a 100-fold drop in lipophilicity with the addition of only two heavy
atoms. 34c was found to be equipotent on chloroquine-sensitive and -resistant cell lines and on both blood and liver stage forms
of the parasite. These data further validate NMT as an exciting drug target in malaria and support 34c as an attractive tool for
further optimization.
■ INTRODUCTION
Malaria is an infectious disease caused by parasites of the genus
Plasmodium and is a world health crisis of paramount urgency.
Malaria was responsible for over 200 million cases and 1 million
deaths in 2010 alone,1 primarily aﬀecting developing countries
and children under the age of 5.2 Although ﬁve species of
Plasmodium parasite are known to infect humans,2,3 two species
are responsible for the majority of morbidity and mortality:
Plasmodium falciparum (Pf) and Plasmodium vivax (Pv). These
species are the focus of the work described in this paper.
The current treatment for malaria is combination therapy,
typically comprising artemisinin derivatives and a companion
drug such as lumefantrine, meﬂoquine, or amodiaquine. These
drugs (and the majority of antimalarials)4,5 target only the
symptomatic blood-stage forms of the parasite; drugs that target
additional life stages (such as asymptomatic liver stage parasites)
are in high demand.6 Furthermore, resistance to chloroquine is
long established7 and signs of artemisinin resistance have been
detected along the eastern8 and western borders9 of Thailand,
compounding the urgent requirement for additional therapeutic
agents targeting Plasmodium parasites.
Although there has been a great deal of funding and expertise
directed toward antimalarial drug discovery over the past decade,
the majority of therapeutics in clinical development are either
elaborations of existing pharmacophores, reformulations/
combinations of existing drugs, or novel molecules that function
by unknown mechanisms of action.10 In order to combat
resistance and achieve the goal of malaria eradication, a range of
therapies targeting a variety of biological mechanisms and
parasite life stages are required.
N-Myristoylation is the covalent attachment of myristate, a
saturated 14-carbon fatty acid, to the N-terminal glycine of target
proteins from the acyl source myristoyl-coenzyme A (CoA). This
transformation is catalyzed by N-myristoyltransferase (NMT), a
monomeric enzyme found ubiquitously in eukaryotes. Myr-
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istoylation is a widespread modiﬁcation that occurs co- and post-
translationally and has hundreds of putative substrates in vivo.11
Furthermore, myristoylation of proteins is known to modulate a
variety of properties (such as protein localization12 and
stability13) and is implicated in a variety of critical biological
pathways.14,15
In the speciﬁc context of malaria, several important parasitic
proteins have been shown to require myristoylation in order to
localize correctly and to carry out their biological functions,16−18
and the genetic essentiality of NMT in P. berghei (Pb), the
infectious species in the murine model of malaria, has been
conﬁrmed by conditional knockdown experiments.19 Further-
more, we recently reported the validation of NMT as an essential
and chemically tractable drug target in P. falciparum. Using an
integrated chemical biology approach, we identiﬁed the NMT
substrate proteins in the blood stage of the parasite and
demonstrated with small molecule tools that on-target inhibition
of myristoylation disrupts the function of multiple speciﬁc
downstream pathways, resulting in rapid cell death.20 Herein, we
describe the development of a previously described series of
benzo[b]thiophene inhibitors into 34c, a potent and selective
parasite NMT inhibitor instrumental to the validation of this
drug target. We also report further investigations into the utility
of NMT inhibitors in drug-resistant cell lines and liver stage
parasites.
■ RESULTS AND DISCUSSION
Previous work reported discovery of a series of benzo[b]-
thiophene-based inhibitors of P. falciparum (Pf)NMT and P.
vivax (Pv)NMT, exempliﬁed by 1 (Figure 1).21 1 represents a
promising starting point for hit to lead development but has only
moderate enzyme aﬃnity and high lipophilicity and contains a
potentially metabolically labile ester group. Further development
therefore focused on removal of this high-risk functionality
combined with a 100-fold improvement in enzyme aﬃnity,
reduced lipophilicity, and controlled molecular weight. Little is
currently known of the potential for toxicity resulting from
mammalian NMT inhibition, and previous data have shown that
a potentHomo sapiens (Hs)NMT inhibitor is not toxic to mice at
high doses.22 Although selectivity over HsNMT is desirable,
selectivity at the cellular level was considered the more critical
determinant for progression.
The metric ligand eﬃciency (LE) has been used extensively in
early stage drug development, and its utility has been well
documented.24 The main criticism of LE is the omission of any
reference to the lipophilicity of the compound in question.
Lipophilicity has been implicated as one of the most important
properties of a potential drug molecule; it is critical to many
related properties including solubility, permeability, and
distribution.25 In vivo, highly lipophilic compounds will be
more likely to partition from plasma to organic components such
as membranes and proteins, increasing biological promiscuity
(and in turn toxicity).26 Furthermore lipophilicity tends to inﬂate
throughout drug development.27 Indeed, a recent review on
metrics in drug discovery has stated “optimizing LE and LLE
(ligand lipophilic eﬃciency, pIC50 − log P) in concert is an
important success factor for hit and lead optimization in drug
discovery projects”.28
Ligand eﬃciency dependent lipophilicity (cLogP/LE, LELP)
has been proposed as a way to incorporate aﬃnity, lipophilicity,
and molecular size into a single metric for the triage of
molecules29 and has been shown to be a strong predictor of
druglikeness.30 It is proposed that a low LELP will reduce the
chance of later stage failure due to nonspeciﬁc toxicity; marketed
drugs have an average LELP of approximately 6, and desirable
leads (LE > 0.3, cLogP < 3) display LELP < 10.29 In order to
control the lipophilicity and molecular weight of the current
series, LELP was used to determine the druglikeness or
physicochemical quality of the inhibitors tested. For clarity, all
LELP values quoted in this work refer to PfNMT LE.
Consideration of the LELP of 1 (13.5, Figure 1) emphasizes
the requirement for signiﬁcant improvement in the physico-
chemical proﬁle of this series.
Previous work showed that an appropriately placed 3-
methoxyphenyl substituent can form π−π and hydrogen bonding
interactions with Phe105 and Ser319 of PvNMT, respectively.31
Attempts to replicate these interactions within the benzothio-
phene series yielded only a small aﬃnity enhancement, but
previously reported crystallographic evidence indicated that
extension of the linker between the ester and methoxyphenyl
moieties might result in improved interactions.21 A series of
phenethyl esters and amides were therefore synthesized and
assayed against a panel of NMTs (Scheme 1, Table 1).
This hypothesis was successfully validated, in that moving
from 1 to 4b produced a 6-fold improvement in PfNMT aﬃnity,
retained the high PvNMT aﬃnity, and pleasingly had little eﬀect
on HsNMT aﬃnity. However, despite this improvement, the
accompanying lipophilic methylene unit resulted in only a
marginally improved LELP. Furthermore, the antiparasitic
activity of 4b was reduced compared to 1.
Further SAR mimicked that described previously for benzyl
esters:31 adding a second hydrogen bond acceptor (4c)
signiﬁcantly improved aﬃnity but removed all selectivity,
resulting in a compound with high aﬃnity against all three
enzymes. Esters are strongly preferred over amides (4a vs 6a, 4d
vs 6b, 4e vs 6c), and the active site for PvNMT appears to be
more promiscuous than that of PfNMT and HsNMT.
Intriguingly, increasing the linker length by a further methylene
(4a vs 4d) reduced aﬃnity for PfNMT, maintained aﬃnity for
Figure 1. 2,3-Substituted benzo[b]thiophene PfNMT and PvNMT inhibitor 1 and the target proﬁle for the development of this series. Footnote a: Ki
values are quoted in place of IC50 values as a means of expressing the inhibitor aﬃnity while correcting for diﬀering Michaelis constants (Km) between
enzymes. Enzyme Ki values are calculated from the IC50 values using the Cheng−Prusoﬀ equation, the deﬁnition of which is given in the Experimental
Section.23 IC50 values are the mean value of two or more determinations, and standard deviation is within 20% of the IC50. Footnote b: No signiﬁcant
diﬀerence in inhibition between HsNMT1 and HsNMT2 isoforms has been observed in this series; therefore, the HsNMT aﬃnities reported in this
work refer toHsNMT1. Footnote c: LELP = cLogP/LE. LE = [−log(Ki)](1.374)/(no. of heavy atoms), with cLogP determined with ChemAxon, which
can be obtained from http://www.chemaxon.com/products/calculator-plugins/logp/.
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PvNMT, and increased aﬃnity for HsNMT. This reinforces the
requirement for the ethyl spacer and indicates that selectivity is
achievable through interactions with residues in this area of the
enzyme. It is notable that the antiparasitic activity of these
compounds is slightly reduced, with only the high aﬃnity 4c
displaying improved activity compared to 1. It may be that the
increased lipophilicity of this series has reduced the free fraction
available for binding. 4c also displays the best LELP score of any
analogues tested; further development shall continue to focus on
targeting a LELP of <10.
Ester Bioisosteric Replacement. The increased linker
length between the phenyl moiety and the ester presented an
excellent opportunity to investigate replacing the ester moiety
with a heterocycle. In earlier analogues this modiﬁcation was not
explored, since it would have resulted in four contiguous
aromatic rings, with likely deleterious eﬀects on the solubility and
toxicity proﬁle. However, the incorporation of an extra
methylene unit adds an extra degree of freedom and interrupts
the π-system, eliminating this potential issue. Crystallography
suggested that the interactions of the ester with the enzyme were
conﬁned to long-distance π-interactions with Tyr211 and
Phe105. In this scenario oxadiazoles are common bioisosteric
replacements for methylene esters,32 displaying increased
biological stability but with similar size and shape and increased
potential for π-interactions. Both 1,2,4-regioisomers were
prepared using complementary routes (Scheme 2).
Replacement of the ester linker with a 1,2,4-oxadiazole
produced an increase in aﬃnity for all three enzymes, presumably
due to π-interactions within the active site and/or increased
rigidiﬁcation of the linker with respect to 4b. A single methylene
between the oxadiazole linker and the phenyl moiety was
preferred (9a vs 9b). Introduction of a m-methoxy substituent
improved aﬃnity, although only by a small degree (9a vs 9c, 14a
vs 14b), and replacement of the methoxy group with a weakly
hydrogen bonding and lipophilic chlorine reduced aﬃnity for all
three enzymes (9c vs 9d). Interestingly, in 4c addition of the
second methoxy substituent produced an increase in aﬃnity
against PfNMT and HsNMT, whereas in 9e selectivity is
improved with respect to 9c. Although this result was quite
promising, the solubility of 9e is very low (data not shown),
limiting the potential of this substitution pattern in further
development. As with the ester extension, this optimization is
accompanied by an increase in heavy atom count resulting in
only a small increase in LELP, still above the target value of 10.
Nonetheless, both isomers of 1,2,4-oxadiazoles appear to be
promising bioisosteres for the potentially problematic ester
functionality.
Improvements in LELP: Capitalizing on Matched
Molecular Pairs Analysis. The developments detailed above
improved enzyme aﬃnity and removed a potentially labile ester
group, making the compound series signiﬁcantly more druglike.
A consideration of LELP across the series highlights that the
increase in enzyme aﬃnity from 1 to 9c has been achieved at the
expense of increased lipophilicity and molecular weight. This
results in only a small improvement in LELP from 13.5 to 12.5,
still substantially above the desired value of 10 for a promising
lead. The optimization of biological potency at the expense of
molecular properties is a common pitfall in drug development
that has been associated with clinical attrition.29 The next stage in
development therefore focused on improving the LELP of the
series by improving aﬃnity while reducing lipophilicity and
molecular weight.
Several strategies for lowering lipophilicity have been
described in the recent literature; one of the most successful is
matched molecular pairs analysis,33 the concept of replacing a
moiety with a “matched pair”, a structural analogue that displays
favorable physicochemical properties. One of the most studied
(and striking) examples is the replacement of 1,2,4-oxadiazoles
with the symmetrical 1,3,4-oxadiazole isomer.34,35 Because of the
contrasting dipole moment of each heterocycle, 1,3,4-oxadia-
zoles display on average 10-fold lower lipophilicity and more
favorable proﬁles with respect to metabolic stability, hERG
inhibition, and aqueous solubility.35 Switching to this matched
pair thus represented an attractive opportunity to lower
lipophilicity and improve physicochemical properties by making
aminimal structural change to the series, crucially without adding
molecular weight. The mixed hydrazide intermediate 17a/b was
synthesized readily from ethyl ester 15, and this was converted
into the 1,3,4-oxadiazole analogue 20a/b, and additionally the
1,2,4-triazole analogue 18 from 17a (Scheme 3). Although less
well studied than 1,3,4-oxadiazoles, 1,2,4-triazoles are known to
have a lower log D than 1,2,4-oxadiazoles,36 as well as a higher
aromatic stabilization energy.37
Triazole 18 displayed a disappointing aﬃnity proﬁle, with no
change in aﬃnity for HsNMT but a decrease in aﬃnity against
the NMTs of the two parasite species (9a, 14a vs 18, Table 2).
Nevertheless, an accompanying decrease in cLogP resulted in a
signiﬁcant improvement in the LELP for 18, 9.5 compared to
12.4 and 12.8 for 9a and 14a, respectively. This scaﬀold is
therefore likely to have improved aqueous solubility and druglike
properties compared to the 1,2,4-oxadiazoles, which will need to
be considered in the future development of this series.
As might be expected from the small diﬀerence in aﬃnity
between the 1,2,4-oxadiazole regioisomers (for example, 9c vs
14b), moving to the 1,3,4-oxadiazole 20a/b had only a small
eﬀect on Pf/Pv NMT aﬃnity (Table 2). However, this
modiﬁcation unexpectedly decreased HsNMT aﬃnity (20b vs
9c, 14b), resulting in a 13-fold selectivity window between
Scheme 1. Synthesis of Phenethyl Esters and Amidesa
aReagents and conditions: (a) 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide, hydroxybenzotriazole, N,N-diisopropylethylamine,
MeCN, rt, 18 h, 36−57%; (b) benzotriazo-1-yl-oxytripyrrolidino-
phosphonium hexaﬂuorophosphate, N,N-diisopropylethylamine,
DCM, rt, 18 h, 69−93%; (c) 10% TFA in DCM (v/v), rt, 2 h, 42−
97%. 2 was prepared as described previously.21
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PfNMT andHsNMT, 24-fold between PvNMT andHsNMT. In
addition to the improved selectivity proﬁle, 20a/b has a
signiﬁcantly lower cLogP than 9a/c and 14a/b, resulting in a
greatly improved LELP. Indeed, 18, 20a, and 20b all display
LELP within the target range for promising lead compounds
(LELP < 10).
Crystallography conﬁrmed the binding mode of 20b in the
peptide substrate pocket of PvNMT (Figure 2A, PDB entry
4CAE), showing that the methoxyphenyl moiety makes
hydrophobic contacts with Phe105 and a polar contact with
Ser319, in addition to the interactions observed previously for
1.21 Furthermore, the oxadiazole is “sandwiched” between the
aromatic residues Phe105 and Tyr211, potentially explaining the
aﬃnity improvement observed when the ester in 4b is replaced
by an oxadiazole in 9c/14b (Figure 2B).
Improvements in LELP: Investigations of the Solvated
Pocket.The crystal structure of 20b bound to PvNMT indicated
that there was a voluminous solvent-ﬁlled pocket surrounding
the methylene group α to the methoxyphenyl, inviting the
introduction of functionality that could either stabilize the water
molecules in this pocket or displace water to the bulk solvent
(Figure 3).38,39 In addition, this position is a potential target for
oxidative metabolism and blocking with alternative substituents
may provide beneﬁts during subsequent lead development.
The abundance of readily available α-substituted phenylacetic
acids meant this strategy could be explored extensively, using
previously developed chemistry: a variety of substitutions were
introduced as shown in Scheme 4 and Table 3.
The results show that a wide variety of substitutions at this
position produce only small changes in enzyme aﬃnity,
Table 1. Enzyme Aﬃnity and Plasmodium falciparum LELP for Phenethyl Esters and Amides
aKi values are the mean value of two or more determinations, and standard deviation is within 20% of the Ki.
bLELP not calculated as enzyme aﬃnity
above measurable range. c3D7 EC50 values are determined using a Sybr Green ﬂuorometric assay.
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reinforcing the notion that there is ﬂexibility in the binding
pocket. Of the hydrophobic substituents, cyclopropyl results in
the highest aﬃnity: thus, 23c retains the activity of 20a but with a
concomitant increase in LELP. The most signiﬁcant result is 23g,
which is approximately equipotent to 23a with the addition of a
polar hydroxyl group. This increases the hydrophilicity and
decreases the LELP but increases the molecular complexity (with
the addition of a stereocenter) and introduces a further hydrogen
bond donor (which may adversely aﬀect membrane perme-
ability). Weighing these detriments against the moderate
improvements these modiﬁcations provided, the decision was
made to progress development with the unsubstituted template
as in 20a/b with the knowledge that functionality could be
reintroduced during future lead development should a
solubilizing/metabolism blocking group be required.
Improvements in LELP: Optimization of Polar Con-
tacts. The next area of interest was modiﬁcation of the
methoxyphenyl portion of the molecule. The rationale for this
change was twofold: (i) the methoxyphenyl portion contributes
signiﬁcantly to the lipophilicity of these molecules and, as such,
presents a target for improvement of LELP;40 (ii) aryl ethers are
notoriously poor H-bond acceptors,41 and so replacement may
result in a stronger hydrogen bond with Ser319 and an
improvement in aﬃnity.
Brand et al. previously described the development of a series of
highly potent Trypanosoma brucei NMT inhibitors42 that form a
hydrogen bond to the conserved Ser319 (Ser330 in Leishmania
major NMT) residue, for example, via a 1,3,5-trimethylpyrazole
moiety (PDB entry 2WSA). Building on this observation, we
selected three distinct heterocycles to replace themethoxyphenyl
substituent (Scheme 5) on the basis that nitrogen atoms
conjugated within π-systems are typically excellent hydrogen
bond acceptors,41 and these moieties would have reduced
lipophilicity relative to the methoxyphenyl parent compound
(Table 4). The binding mode in PvNMT (Figure 2) indicated
that the heterocycles in molecules 34a−c (bearing a methylene
linker) would not make direct contacts to the desired residues.
For this reason, compounds 35a−cwith an extended two-carbon
linker were also synthesized in the expectation that this would
place the heterocycle directly adjacent to Ser319, albeit with the
entropic and lipophilic penalty associated with a longer alkyl
chain.
The SAR obtained across these analogues was unexpected: in
all cases PvNMT and PfNMT had higher aﬃnity for the
methylene linked 34 series, although this was not always the case
for HsNMT (34b vs 35b). Of the three heterocycles, isoxazoles
(34b and 35b) and 1H-pyrazoles (34a and 35a) had decreased
aﬃnity compared to the methoxyphenyl parent 20b. Interest-
ingly, 34a displays 30-fold selectivity between PfNMT and
HsNMT, a signiﬁcant improvement over the 8- to 9-fold
observed in 34b/34c.
Addition of the N-methyl group in 34c produces a marked
increase in aﬃnity against all enzymes, resulting in the highest
Scheme 2. Synthesis of TwoRegioisomers of 1,2,4-Oxadiazole
Bioisosteresa
aReagents and conditions: (a) NH2OH·H2O, EtOH, rt, 5 h, 98−99%;
(b) 2, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydroxyben-
zotriazole, DMF, 140 °C, 3 h, 10−31%; (c) 10% TFA in DCM (v/v),
rt, 2 h, 13−99%; (d) bromoacetonitrile, t-BuOK, THF, 0 °C to rt, 15
min, 88%; (e) tert-butyl 4-hydroxypiperidine-1-carboxylate, diisopropyl
azodicarboxylate, PPh3, THF, rt 1.5 h, 78%; (f) RCH2CO2H, 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide, hydroxybenzotriazole,
MeCN, rt, 18 h; (g) 4 Å molecular sieves, toluene, 18 h, 110 °C,
54−68% over two steps.
Scheme 3. Synthesis of 1,3,4-Oxadiazole and 1,2,4-Triazole
Linker Bioisosteresa
aReagents and conditions: (a) NH2NH2·H2O, EtOH, 78 °C, 24 h,
75%; (b) RCH2C(O)Cl, N,N-diisopropylethylamine, DCM, rt, 15
min, 75−91%; (c) POCl3, 100 °C, 1 h; (d) ammonium acetate, acetic
acid, 140 °C, 1.5 h, 6% over two steps; (e) TsCl, 1,2,2,6,6
pentamethylpiperidine, DCM, rt, 3 h, 48−65%; (f) TFA, DCM, rt, 2
h, 55−98%.
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aﬃnity Plasmodium spp. NMT inhibitor reported to date with
single-digit nanomolar Ki against both enzymes. Furthermore,
this compound displays nanomolar eﬃcacy against the parasite,
allowing further biological evaluation of this drug target (vide
infra). The aﬃnity enhancement imparted by the methylpyrazole
is accompanied by a reduction in cLogP (relative to
methoxyphenyl 20b) resulting in an excellent LELP of 5.5,
close to the reported average LELP of marketed drugs.29
Table 2. Enzyme Aﬃnity and LELP of Bioisosteric Heterocycle-Linked Inhibitors
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Consequently, this compound has excellent druglike properties;
we have previously reported the excellent aqueous solubility (>8
mM) and in vitro pharmacokinetic properties of this molecule.20
Although the selectivity between PfNMT and HsNMT is 8-fold
(30-fold vs PvNMT), comparison to 34a shows that signiﬁcant
changes in the selectivity proﬁle may potentially be achieved by
altering the interactions with this binding pocket.
The binding mode of 34cwas elucidated by crystallography, as
brieﬂy described previously20 (Figure 4, PDB entry 2YNE). As
predicted during the compound design process, the pyrazole of
34c does not directly interact with the target Ser319, indicating a
subtler basis for the aﬃnity improvement. The pyrazole N-2
interacts indirectly with Ser319 via a water molecule, with the
methyl groups occupying hydrophobic regions of the pocket
(Figure 4B). The improved enzyme aﬃnity is likely a result of the
strong pyrazole−water hydrogen bond combined with ﬁt
complementarity within the binding site. In addition, the
compound makes all the interactions observed with previous
members of the series, including the salt bridge interaction with
Leu410/Tyr107, a sandwiched oxadiazole linker, and deeply
buried benzothiophene scaﬀold (Figure 4A).
The binding mode of 34a in PvNMT was also determined by
crystallography (Figure 5A, PDB entry 4CAF). This compound
displays a ∼40-fold lower binding aﬃnity to PvNMT than 34c;
however, the binding modes of these two compounds are
extremely similar (Figure 5B). The only point of diﬀerentiation is
the pyrazole heterocycle which forms a direct polar interaction
with Ser319 as opposed to the water-bridged interaction
observed in Figure 4B. Indeed, this water molecule is excluded
from the pocket occupied by 34a, perhaps indicating that it is
involved in stabilizing Ser319 and therefore that its expulsion to
the bulk solvent is energetically unfavorable.
Blood and Liver Stage in Vitro Cellular Activity. 34c
provides excellent enzyme aﬃnity and LELP, and the cellular
eﬃcacy enabled further biological evaluation of this inhibitor.
34c was tested against a variety of parasites in vitro, including
both drug-resistant cell lines and liver stage parasites, and for
mammalian cell toxicity against human hepatocellular carcinoma
cell line HepG2. Activity was directly compared to chloroquine
(36) and atovaquone (37) where relevant.
3D7 and NF54 are chloroquine-sensitive strains of the
parasite, whereas K1 and Dd2 are chloroquine-resistant strains,
as evidenced by the greatly reduced potency of this drug against
these strains (Table 5). 34c was previously shown to act on-
target in blood stage drug-sensitive (3D7) parasites.20 Pleasingly,
34c is active against an additional drug-sensitive line (NF54) and
there is very little loss of potency for drug-resistant cell lines (less
than 4-fold between NF54 and Dd2), indicating that NMT
inhibition may be an eﬀective mechanism to target drug-resistant
parasites in a clinical context.
In addition, 34c was tested against a Plasmodium berghei (Pb)
liver stage model to determine whether NMT is likely to be a
viable drug target for clearance of liver stage parasites. The
PbNMT enzyme aﬃnity of 34c was determined at 14 nM,
validating an approximate comparison with the Pf blood stage
Figure 2. X-ray crystal structure of 20b (blue) bound to PvNMT
(green). (A) 20b bound to PvNMT. The 3-methoxyphenyl substituent
forms the intended interactions with Ser319 and Phe105, in addition to
the deeply buried hydrophobic scaﬀold and salt bridge interaction
observed in 1. (B) The oxadiazole linker is sandwiched between two
aromatic residues, rationalizing the aﬃnity enhancement in moving to
an aromatic heterocycle from the ester linker in 4b. Dashed lines are
drawn to highlight key interactions between the enzyme and the ligand.
Figure 3. X-ray crystal structure of 20b (blue) bound to PvNMT
(green). Further inspection of the water molecules within the active site
shows that the benzylic CH2 occupies a heavily solvated pocket,
indicating that substitution may result in more favorable energetics
within the enzyme active site. Dashed lines indicate water molecules
within 5 Å of the benzylic position.
Scheme 4. Synthesis of α-Substituted Phenyl 1,3,4-Oxadiazole Inhibitorsa
aReagents and conditions: (a) Ph-CR1R2-CO2H, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, hydroxybenzotriazole, THF, DMF,
rt, 18 h, 48−99%; (b) TsCl, 1,2,2,6,6pentamethylpiperidine, DCM, rt, 18 h; (c) 10% TFA in DCM (v/v), rt, 2 h, 4−40% over two steps.
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models. 34c had a liver stage EC50 of 372 nM, which, although
signiﬁcantly lower than the atovaquone standard, is in excellent
agreement with the blood stage results. This provides evidence
that NMT inhibition is also a promising mechanism for targeting
liver stage parasites andmay therefore be an eﬀective pathway for
the disruption of multiple parasite life stages.
Lastly, 34c displays up to ∼40-fold selectivity between
parasitic and HepG2 cell lines (14-fold in the case of Dd2).
This represents an encouraging window for a compound with 10-
fold enzyme selectivity: if HepG2 cytotoxicity is due to NMT
inhibition, then a more selective compound will have a larger
window, and if the lethality is nonspeciﬁc, then the cell potency
and toxicity appear suﬃciently decoupled to be optimized
independently. The Medicines for Malaria Venture dictates that
validated hit compounds should display cellular selectivity of
greater than 10-fold, whereas preclinical candidates should be
>100-fold selective.43 With this target in mind, 34c displays
reasonable selectivity for a lead compound: a further 3-fold
improvement in eﬃcacy without accompanying toxicity will
achieve the required window for a candidate molecule. Note that
Table 3. Enzyme Aﬃnity and LELP of α-Substituted Phenyl 1,3,4-Oxadiazole Inhibitors
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the moderate selectivity is a functional of low eﬃciacy rather than
high toxicity; the LD50 for 34c is approximately the top
concentration tested (10 μM) for the antimalarial standards.
Eﬀects of LELP on Cellular Activity. The metric LELP was
used to guide the development of this compound series, based on
the hypothesis that compounds with a low LELP (ideally <10)
will have fewer oﬀ-target eﬀects and as a result are more
druglike.29 In an attempt to assess if LELP is a useful metric in
this regard, the cellular EC50 against the 3D7 parasite line was
plotted against NMT aﬃnity for all tested members of this series.
Analysis of the EC50/Ki correlation is shown in Figure 6.
An initial assessment of cellular potency vs enzyme aﬃnity
showed only a weak correlation (R2 = 0.47) between these two
parameters (Figure 6A) and a relatively ﬂat gradient (0.40).
However, when the compounds were separated into those with a
leadlike LELP score (LELP < 10) and those without (LELP >
10), a qualitative assessment showed an improved correlation for
those compounds with a low LELP value (Figure 6C vs Figure
6B). Figure 6C shows that for those compounds with LELP < 10
there is a strong correlation between cellular potency and
enzyme aﬃnity (R2 = 0.82) and a gradient signiﬁcantly closer to 1
than in the full data set (0.75 vs 0.40). In contrast, for compounds
with a LELP of >10 there is a very weak correlation between EC50
and Ki (R
2 = 0.36) and a ﬂat gradient (0.23), indicating that
antiparasitic activity from these compounds derives predom-
inantly from a mechanism independent of NMT inhibition.
This observation is consistent with the hypothesis that high-
LELP compounds (with relatively high lipophilicity and low LE)
are more promiscuous than low-LELP analogues29 and therefore
may exhibit cytotoxic activity by a variety of nonspeciﬁc
mechanisms. Low-LELP analogues are predicted to bind more
speciﬁcally to the target enzyme, and this is supported by the
improved correlation between NMT aﬃnity and antiparasitic
activity in this data set; although wary of “correlation inﬂation”,44
this analysis appears to provide a robust predictor of cell eﬃcacy
when applied to these models. It would be unwise to invoke
LELP < 10 as a rule rather than a guideline, as this is unlikely to be
a binary boundary, with some compounds in either subset
behaving not as predicted. Nevertheless, it provides encouraging
evidence that LELP is a useful metric for guiding the hit-to-lead
optimization process. Furthermore, this analysis highlights the
danger of assuming that weakly active (LE < 0.3), lipophilic
compounds (cLogP > 3) function in cellular systems by the
presumed mechanism of action, without further validation.
■ CONCLUSION
Previously reported work described the discovery of 1 by a lead-
hopping approach, as a ligand eﬃcient inhibitor of plasmodial
NMT.21 This work details LELP-guided development of this
series, optimizing enzyme aﬃnity while retaining selectivity over
HsNMT to yield 34c, a high aﬃnity druglike plasmodial NMT
inhibitor. Development from 1 to 34c achieved a 100-fold
improvement in enzyme aﬃnity coupled with a 100-fold
reduction in lipophilicity, at the expense of only two additional
heavy atoms. This further demonstrates the utility of medicinal
chemistry strategies such as matched molecular pairs analysis,
bioisosterism, and metric-guided optimization in hit-to-lead
development.
34c has antiparasitic activity in vitro, exhibiting similar potency
over four parasite strains including two drug-resistant ones. In
addition, this compound is equipotent against blood and liver
stage parasites and displays selectivity over human liver host cells.
It has been previously shown that this molecule exerts its
antiparasitic activity via inhibition of NMT and moreover that it
can reduce parasitemia in vivo.20 Taken together, this biological
characterization shows that NMT is a highly promising target for
the development of a new generation of antimalarial drugs.
Further work will focus on optimization of cellular potency and
in vivo pharmacokinetics, with the aim of producing a candidate
series for the treatment of malaria.
Scheme 5. Synthesis of Five-Membered Heterocyclic Methoxyphenyl Replacementsa
aReagents and conditions: (a) NaH, ethyl bromoacetate, THF, 0 °C, 18 h, 78%; (b) methyl 3-bromopropionate, K2CO3, DMF, 55 °C, 18 h, 30%;
(c) NH2NH2·H2O, MeOH, rt, 3 h, 83−99%; (d) n = 1, NH2OH·HCl, K2CO3, EtOH, 78 °C, 3 h, 12%; n = 2, NH2OH·HCl, H2O, MeOH, 60 °C, 18
h, 89%; (e) MeNHNH2, AcOH, 3 h, rt, 73−95%; (f) LiOH·H2O, MeOH, rt, 18 h, 51−95%; (g) 16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride, hydroxybenzotriazole, THF, DMF, rt, 18 h, 48−99%; (h) TsCl, 1,2,2,6,6-pentamethylpiperidine, DCM, rt, 18 h; (i) 10% TFA in
DCM (v/v), rt, 2 h, 3−26% over two steps.
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■ EXPERIMENTAL SECTION
General. All chemicals were purchased from Sigma-Aldrich Ltd.
(Gillingham, UK), Acros Organics (Geel, Belgium) and Alfa Aesar
(Heysham, UK) and used without further puriﬁcation. Moisture
sensitive reactions were performed under nitrogen atmosphere using
dried glassware, anhydrous solvents, and standard syringe/septa
techniques.
Silica gel normal phase column chromatography was performed on an
Isolera (Biotage, U.K.) automated apparatus with SNAP silica cartridges
(Biotage, U.K.). Mobile phase consisted of n-hexane (solvent A) and
ethyl acetate (solvent B), and standard gradient consisted of x% solvent
B for 1 column volumes, x% to y% B for 10 column volumes, and then y
% B for 2 column volumes. x and y are deﬁned in the characterization
section of the compound of interest.
Final compounds were puriﬁed by one of two methods: either HPLC
or LC−MS. Postchromatography, organic solvents were removed by
partial evaporation under reduced pressure and then compounds were
dried by lyophilization overnight.
HPLC involved the following: Gilson semipreparative reverse phase
HPLC system equipped with a HICHROM C18 column (250 mm ×
21.2 mm), no. 306 pumps, and a Gilson UV/vis detector, detecting at
Table 4. Enzyme Aﬃnity and LELP of Heterocyclic Methoxyphenyl Replacements
Figure 4. Binding mode of 34c (gold) bound to PvNMT. (A) 34c
(gold) bound to PvNMT (green), showing piperidine−Leu410 salt
bridge interaction, deeply buried benzothiophene scaﬀold, and 1,3,5-
trimethylpyrazole heterocycle bound within the Ser319 hydrophobic
pocket. (B) Enlarged view of the 1,3,5-trimethylpyrazole of 34c (gold)
with PvNMT (green). This shows the water-bridged interaction
between the pyrazole and Ser319, as well as multiple hydrophobic
contacts between the heterocycle and the binding pocket.
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220 nm. Themobile phase consisted of H2O + 0.1% formic acid (solvent
A) and MeOH + 0.1% formic acid (solvent B), with an elution method
of 0−2min 50% B, 2−30min 50−98% B, 30−32min 98%, 32−32.5 min
2% B at a ﬂow rate of 12 mL/min.
LC−MS involved the following: RP-HPLC/MS on a Waters 2767
system equipped with a photodiode array and an ESI mass spectrometer
using a XBridge Prep C18 (5 μm, 19 mm × 100 mm) column, equipped
with an XBridge Prep C18 guard column (5 μm, 19 mm × 10 mm). The
following elution method was used: gradient of solvent A and solvent B
(as above) of 0−10 min 50−98% B, 10−12 min 98% B, 12−13 min 98−
50% B, 13−17 min 50% B. Flow rate was 20 mL/min.
The purity of the title compounds was veriﬁed by reverse phase LC−
MS on a Waters 2767 system equipped with a photodiode array and an
ESI mass spectrometer using a XBridge C18 (5 μm, 4.6 mm × 100 mm)
column, equipped with an XBridge C18 guard column (5 μm, 4.6 mm ×
20 mm). The following elution method was used: gradient of solvent A
and solvent B (as above) of 0−10min 5−98%B, 10−12min 98% B, 12−
13min 98−5% B, 13−17min 5% B. Flow rate was 1.2 mL/min. Purity of
tested compounds was ≥95% unless otherwise speciﬁed.
1H and 13C NMR spectra were respectively recorded on 400 and 101
MHz Bruker AV instruments at room temperature unless speciﬁed
otherwise. In these cases 1H and 13C NMR spectra were respectively
recorded on 500 and 126 MHz Bruker AV instruments at room
temperature and were referenced to residual solvent signals. Data are
presented as follows: chemical shift in ppm, integration, multiplicity (br
= broad, app = apparent, s = singlet, d = doublet, t = triplet, q = quartet, p
= pentet, m = multiplet), and coupling constants in Hz.
Mass spectra were obtained from the Mass Spectrometry Service of
Department of Chemistry, Imperial College London.
Prototypical Procedure for Preparation of Ester Family 4. 1
and 2 were prepared as described previously.21
tert-Butyl 4-((2-(((3-Methoxybenzyl)oxy)carbonyl)benzo[b]-
thiophen-3-yl)oxy)piperidine-1-carboxylate (3b). To a solution of 2
(50 mg, 0.13 mmol) in dry acetonitrile (2 mL) were added
hydroxybenzotriazole (27 mg, 0.20 mmol), N,N-diisopropylethylamine
(26 μL, 0.16 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (30 mg, 0.16 mmol). The reaction mixture
was stirred at room temperature for 15 min. 2-(3-Methoxyphenyl)-
ethanol (22 μL, 0.15 mmol) was then added and reaction mixture
allowed to stir at room temperature for 18 h. The reaction mixture was
concentrated under reduced pressure, dissolved in 10 mL of saturated
ammonium chloride solution, and 3bwas extracted with 3× 10mL ethyl
acetate. Combined organic layers were then washed with brine (10 mL),
dried over magnesium sulfate, concentrated under reduced pressure and
crude product was puriﬁed by ﬂash chromatography (10g SNAP
cartridge, 6−50% B, Rf = 5.1 column volumes) to give 3b as a colorless
oil (24 mg, 36%). 1H NMR (CDCl3, δ, ppm) 7.86 (1H, d, J = 8.0), 7.75
(1H, d, J = 8.2), 7.51−7.46 (1H, m), 7.43−7.37 (1H, m), 7.32 (1H, dd, J
= 8.0, 7.8), 7.04 (1H, d, J = 7.8), 7.02−7.00 (1H, m), 6.90 (1H, dd, J =
Figure 5. Binding mode of 34a (pink) bound to PvNMT. (A) 34a
(pink) forms all previously observed interactions with the enzyme. (B)
Comparison of the binding modes of 34a and 34c reaﬃrms this
similarity, showing that the only point of diﬀerentiation is in the
Phe105/Ser319 binding site occupied by the pyrazole. (C) Enlarged
view of the 1,3,5-trimethylpyrazole of 34c (gold) and 3,5-dimethylpyr-
azole of 34a (pink) with PvNMT (green). The pyrazole of 34a forms a
direct interaction with Ser319 (3.2 Å), and the water involved in the
bridged interaction in Figure 4B has been excluded from the pocket.
Table 5. In Vitro Cellular Assay Data for 34c against Both Parasitic and Human Cells, Compared to Chloroquine (36) and
Atovaquone (37)
aNF54, K1, and Dd2 EC50 values are determined using a [
3H]hypoxanthine incorporation assay (performed by Dr. Sergio Wittlin and Dr. Christian
Scheurer, Swiss Tropical and Public Health Institute). bP. berghei liver stage EC50 values determined using a luciferase bioluminescence assay. EC50
value is the mean of two determinations. Standard deviation is within 50% of the EC50.
cLD50 values determined using an MTS cellular viability assay.
LD50 value is the mean of six determinations. Standard deviation is within 20% of the LD50.
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8.0, 2.3), 5.35 (2H, s), 4.74−4.66 (1H, m), 3.94−3.86 (2H, m), 3.84
(3H, s), 3.07−2.98 (2H, m), 1.98−1.88 (2H, m), 1.85−1.73 (2H, m),
1.48 (9H, s).
3-Methoxyphenethyl 3-(Piperidin-4-yloxy)benzo[b]thiophene-2-
carboxylate (4b). To a solution of 3b (23.0 mg, 0.05 mmol) in
dichloromethane (1 mL) was added triﬂuoroacetic acid (100 μL), and
the solution was stirred at room temperature for 2 h. The reaction
mixture was concentrated under reduced pressure and puriﬁed by
HPLC, yielding 4b as a colorless oil (5 mg, 18%). tR = 12.3 min;
1H
NMR (CDCl3, δ, ppm) 7.82 (1H, d, J = 8.0), 7.76 (1H, d, J = 8.1), 7.56−
7.48 (1H, m), 7.47−7.40 (1H, m), 7.33 (1H, app t, J = 7.9), 7.04 (1H, d,
J = 7.4), 7.01−6.98 (1H, m), 6.91 (1H, dd, J = 8.2, 2.4), 5.34 (2H, s),
4.88−4.81 (1H, m), 3.84 (3H, s), 3.54−3.44 (2H, m), 3.11−3.01 (2H,
m), 2.22−2.11 (4H, m); 13C NMR (CDCl3, δ, ppm) 161.48, 159.84,
153.90, 138.23, 136.98, 134.06, 129.82, 128.39, 125.07, 123.14, 122.61,
120.34, 115.87, 113.81, 113.79, 76.10, 66.82, 55.29, 41.01, 28.07; ESI
HRMS, found 398.1425 (C22H24NO4S, [M + H]
+, requires 398.1426).
Prototypical Procedure for Preparation of 1,2,4-Oxadiazole
(9/14b). tert-Butyl 4-((2-(3-Benzyl-1,2,4-oxadiazol-5-yl)benzo[b]-
thiophen-3-yl)oxy)piperidine-1-carboxylate (8a). To a solution of 2
(40 mg, 0.11 mmol) in N,N-dimethylformamide (1 mL) were added
hydroxybenzotriazole (16 mg, 0.12 mmol) and 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide hydrochloride (22 mg, 0.12 mmol), and the
reaction mixture was stirred at room temperature for 30 min. N′-
Hydroxy-2-phenylacetimidamide was added (17.5 mg, 0.12 mmol), and
the mixture was stirred at 140 °C for 3 h. The reaction mixture was
concentrated under reduced pressure, dissolved in 20 mL of saturated
ammonium chloride solution, and 8a was extracted with 3 × 20 mL of
ethyl acetate. The combined organic layers were washed with saturated
potassium carbonate solution (20 mL), brine (20 mL), dried over
magnesium sulfate, concentrated under reduced pressure and crude
product was puriﬁed by ﬂash chromatography (10 g SNAP cartridge, 6−
50% B, Rf = 7.5 column volumes) to give 8a as a clear yellow oil (16 mg,
31%). 1H NMR (CDCl3, δ, ppm) 7.87 (1H, d, J = 7.8 Hz), 7.80 (1H, d, J
= 8.0Hz), 7.50 (1H, ddd, J = 8.0, 7.1, 1.2 Hz), 7.46−7.28 (6H, m), 4.63−
4.54 (1H, m), 4.16 (2H, s), 3.98−3.87 (2H, m), 3.00−2.91 (2H, m),
2.01−1.93 (2H, m), 1.90−1.78 (2H, m), 1.49 (9H, s).
3-Benzyl-5-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-1,2,4-ox-
adiazole (9a). 9a was prepared as in 4b replacing 3b with 8a (16 mg,
0.03 mmol) and puriﬁed by LC−MS, yielding 9a as a white solid (12 mg,
94%). tR = 4.22 min;
1HNMR (CDCl3, δ, ppm) 7.82 (2H, d, J = 8.1 Hz),
7.52 (1H, dd, J = 8.1, 7.1 Hz), 7.46 (1H, dd, J = 8.1, 7.1 Hz), 7.40−7.28
(5H, m), 4.80−4.72 (1H, m), 4.16 (2H, s), 3.56−3.45 (2H, m), 3.04−
2.95 (2H, m), 2.22−2.15 (4H, m); 13C NMR (CDCl3, δ, ppm) 170.28,
169.61, 152.34, 137.32, 135.57, 133.82, 129.29, 128.92, 128.37, 127.44,
125.57, 123.45, 122.72, 109.93, 76.97, 40.73, 32.49, 28.4l; ESI HRMS,
found 392.1425 (C22H22N3O2S, [M + H]
+, requires 392.1433).
3-Hydroxybenzo[b]thiophene-2-carbonitrile (10). To a solution of
methyl-2-mercaptobenzoate (1.64 mL, 11.9 mmol) and 2-bromoaceto-
nitrile (0.92 mL, 13.1 mmol) in dry tetrahydrofuran (100 mL) at 0 °C
was added potassium tert-butoxide (5.14 g, 71.3 mmol) gradually over 2
min. The reaction mixture was stirred and allowed to warm to room
temperature over 15 min, quenched with 2M hydrochloric acid to pH 2,
and diluted with 75 mL of water. 10 was immediately extracted with 3 ×
75 mL portions of ethyl acetate. The organic layers were combined,
washed with 75 mL of brine, dried over magnesium sulfate, and
concentrated under reduced pressure to give desired product 10 as a
dark brown solid (2.03 g, 88%). 1H NMR (CDCl3, δ, ppm) 8.54 (1H,
brs), 7.91 (1H, d, J = 8.1 Hz), 7.73 (1H, d, J = 8.2 Hz), 7.62−7.50 (1H,
m), 7.51−7.40 (1H, m).
tert-Butyl 4-((2-Cyanobenzo[b]thiophen-3-yl)oxy)piperidine-1-
carboxylate (11). To a solution of 10 (500 mg, 2.85 mmol) in
tetrahydrofuran (7.5 mL) was added tert-butyl 4-hydroxypiperidine-1-
carboxylate (1.15 g, 5.71 mmol) and triphenylphosphine (1.50 g, 5.71
mmol). The reaction mixture was stirred under nitrogen for 20 min and
cooled to 0 °C, and diisopropyl azodicarboxylate (1.12 mL, 5.71 mmol)
in tetrahydrofuran (10 mL) was added dropwise over 5 min. Reaction
mixture was allowed to warm to room temperature and stirred for 1.5 h,
then concentrated under reduced pressure and the crude product
puriﬁed by ﬂash chromatography (100 g SNAP cartridge, 2−18% B, Rf =
8.5 column volumes) to give 11 as a white solid (800 mg, 78%). 1H
NMR (CDCl3, δ, ppm) 7.85 (1H, dd, J = 8.2, 0.9Hz), 7.72 (1H, d, J = 8.2
Hz), 7.55 (1H, ddd, J = 8.2, 7.1, 1.1 Hz), 7.44 (1H, ddd, J = 8.2, 7.2, 0.9
Hz), 5.25 (1H, tt, J = 7.3, 3.6 Hz), 3.85−3.74 (2H, m), 3.46−3.36 (2H,
m), 2.18−2.07 (2H, m), 1.98−1.87 (2H, m), 1.49 (9H, s).
(Z)-tert-Butyl 4-((2-(N′-Hydroxycarbamimidoyl)benzo[b]-
thiophen-3-yl)oxy)piperidine-1-carboxylate (12). To a solution of
11 (100 mg, 0.28 mmol) in ethanol (2 mL) was added hydroxylamine as
50% aqueous solution (170 μL, 2.79 mmol), and reaction mixture was
stirred under reﬂuxing conditions for 4 h. Reaction mixture was
concentrated under reduced pressure to give 12 as a white solid (109
mg, 99%). 1H NMR (CDCl3, δ, ppm) 7.77−7.73 (1H, m), 7.72−7.67
(1H, m), 7.41−7.37 (2H, m), 6.25 (1H, brs), 5.55 (2H, brs), 4.50−4.41
(1H, m), 4.17−3.99 (2H, m), 2.87 (2H, ddd, J = 14.2, 11.7, 2.6 Hz),
2.12−2.00 (2H, m), 1.87−1.74 (2H, m), 1.48 (9H, s).
tert-Butyl 4-((2-(5-(3-Methoxybenzyl)-1,2,4-oxadiazol-3-yl)benzo-
[b]thiophen-3-yl)oxy)piperidine-1-carboxylate (13b).To a solution of
3-methoxyphenylacetic acid (31 mg, 0.19 mmol) in acetonitrile (1 mL)
were added hydroxybenzotriazole (27.5 mg, 0.21 mmol) and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (39 mg, 0.21
Figure 6. (A) Plot of cellular potency vs enzyme aﬃnity for all members
of this series tested in both assays. (B) Plot of cellular potency vs enzyme
aﬃnity for all compounds with a LELP of >10. (C) Plot of cellular
potency vs enzyme aﬃnity for all compounds with a LELP of <10.
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mmol), and reaction mixture was stirred at room temperature for 15
min. 12 was added (80 mg, 0.21 mmol) and the mixture stirred at room
temperature for 18 h. The reaction mixture was diluted with 20 mL of
0.5 M NaOH(aq) solution, and 13b was extracted with 3 × 20 mL of
ethyl acetate. The combined organic layers were washed with saturated
potassium carbonate solution (20 mL), brine (20 mL), dried over
sodium sulfate, and concentrated under reduced pressure. Crude
product (120 mg) and 4 Å molecular sieves (200 mg) were dissolved in
toluene (3 mL), and reaction mixture was stirred at 110 °C for 18 h. The
reaction mixture was ﬁltered, concentrated under reduced pressure and
crude product puriﬁed by ﬂash chromatography (10g SNAP cartridge,
5−40% B, Rf = 8.0 column volumes) to give 13b as a clear orange oil (66
mg, 68%). 1HNMR (CDCl3, δ, ppm) 7.84 (1H, dd, J = 7.1, 1.2 Hz), 7.79
(1H, dd, J = 7.1, 1.2 Hz), 7.43 (2H, dd, J = 7.1, 1.2 Hz), 7.33−7.28 (1H,
m), 6.97 (1H, d, J = 8.0 Hz), 6.95−6.92 (1H, m), 6.87 (1H, dd, J = 8.0,
2.4Hz), 4.60−4.50 (1H,m), 4.28 (2H, s), 4.00−3.89 (2H, m), 3.83 (3H,
s), 3.02−2.93 (2H, m), 2.01−1.92 (2H, m), 1.89−1.77 (2H, m), 1.48
(9H, s).
5-(3-Methoxybenzyl)-3-(3-(piperidin-4-yloxy)benzo[b]thiophen-
2-yl)-1,2,4-oxadiazole (14b). 14b was prepared as in 4b replacing 3b
with 13b (66 mg, 0.13 mmol) and puriﬁed by HPLC, yielding 14b as a
white solid (21 mg, 40%). tR = 9.7 min;
1H NMR (CDCl3, δ, ppm) 8.03
(1H, dd, J = 7.0, 1.3 Hz), 7.92−7.84 (1H, m), 7.58−7.47 (2H, m), 7.31
(1H, app t, J = 7.9 Hz), 7.04−7.00 (1H, m), 6.99−6.94 (1H, m), 6.94−
6.87 (1H, m), 4.66 (1H, tt, J = 7.7, 3.6 Hz), 4.43 (2H, s), 3.76 (3H, s),
3.44−3.27 (2H, m), 3.03−2.90 (2H, m), 2.13−2.03 (2H, m), 2.01−1.89
(2H, m); 13C NMR (CDCl3, δ, ppm) 178.57, 162.84, 159.46, 149.67,
136.80, 135.25, 133.88, 129.86, 127.34, 125.28, 123.55, 122.15, 121.40,
115.13, 112.72, 112.35, 76.88, 55.09, 40.82, 31.85, 28.20; ESI HRMS,
found 422.1534 (C23H24N3O3S, [M + H]
+, requires 422.1538).
Prototypical Procedure for Preparation of 1,3,4-Oxadiazole
(23a). tert-Butyl 4-((2-(Hydrazinecarbonyl)benzo[b]thiophen-3-yl)-
oxy)piperidine-1-carboxylate (16). To a solution of 15 (300 mg, 0.74
mmol) in ethanol (1 mL) was added hydrazine monohydrate (145 μL,
2.96 mmol). The reaction mixture was heated under reﬂuxing
conditions for 24 h and then concentrated under reduced pressure,
yielding 16 as a yellow oil (217 mg, 75%). 1H NMR (CDCl3, δ, ppm)
7.79 (1H, d, J = 7.6 Hz), 7.74 (1H, d, J = 7.2 Hz), 7.48−7.37 (2H, m),
4.58 (1H, tt, J = 9.8, 4.1 Hz), 4.13−4.04 (2H, m), 2.95−2.82 (2H, m),
2.14−2.05 (2H, m), 1.92−1.78 (2H, m), 1.48 (9H, s).
tert-Butyl 4-((2-(2-(2-Phenylpropanoyl)hydrazinecarbonyl)benzo-
[b]thiophen-3-yl)oxy)piperidine-1-carboxylate (21a).To a solution of
16 (48 mg, 0.12 mmol) in tetrahydrofuran/N,N-dimethylformamide
(4:1 v/v, 0.6 mL) were added hydroxybenzotriazole (8 mg, 0.06 mmol),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (28
mg, 0.15 mmol) and 2-phenylpropanoic acid (20 μL, 0.15 mmol).
Reaction mixture was stirred at room temperature for 18 h and then
diluted with 1.0 M NaOH(aq) (4 mL). 21a was extracted with EtOAc (2
× 5 mL). Combined organic layers were washed with brine (5 mL),
dried over sodium sulfate, and concentrated under reduced pressure,
yielding 21a as a colorless oil (63 mg, 98%). 1H NMR (CDCl3, δ, ppm)
7.82−7.76 (2H, m), 7.49−7.20 (7H, m), 4.68 (1H, tt, J = 10.0, 4.1 Hz),
4.19−4.06 (2H, m), 3.85 (1H, q, J = 7.2 Hz), 2.88−2.79 (2H, m), 2.16−
2.05 (2H, m), 2.02−1.88 (2H, m), 1.60 (3H, d, J = 7.2 Hz), 1.48 (9H, s).
2-(1-Phenylethyl)-5-(3-(piperidin-4-yloxy)benzo[b]thiophen-2-yl)-
1,3,4-oxadiazole (23a). To a solution of 21a (63 mg, 0.12 mmol) and
1,2,2,6,6-pentamethylpiperidine (47 μL, 0.26 mmol) in dichloro-
methane (1 mL) was added m-toluenesulfonyl chloride (25 mg, 0.13
mmol), and the reaction mixture was stirred at room temperature for 18
h. The reaction mixture was then diluted with a further 2 mL of
dichloromethane, washed with water (2 mL), washed with 1.0 M
NaOH(aq) (2 mL), washed with brine (2 mL), dried over magnesium
sulfate, and concentrated under reduced pressure. Crude reaction
mixture was Boc-deprotected without further puriﬁcation as in 4b,
replacing 3b with 22a (10 mg, 0.02 mmol), and puriﬁed by HPLC
yielding 23a as a yellow oil (7 mg, 14%). tR = 11.0 min;
1H NMR
(CDCl3, δ, ppm) 8.44 (1H, brs), 7.85−7.73 (2H, m), 7.54−7.30 (7H,
m), 4.65 (1H, brs), 4.44 (1H, q, J = 6.6 Hz), 3.53−3.35 (2H, m), 3.06−
2.86 (2H, m), 2.20−2.01 (4H, m), 1.84 (3H, d, J = 6.6 Hz); ESI HRMS,
found 406.1587 (C23H24N3O2S, [M + H]
+, requires 406.1589).
Procedure for Preparation of 34c. Ethyl 3-Acetyl-4-oxopenta-
noate (24). To a solution of sodium hydride (576 mg, 24.0 mmol) in
anhydrous tetrahydrofuran (30 mL) cooled to 0 °C was added pentane-
2,4-dione (2.05 mL, 20.0 mmol) in anhydrous tetrahydrofuran (40mL),
and the mixture was stirred for 1 h. Ethyl bromoacetate (2.66 mL, 24.0
mmol) in anhydrous tetrahydrofuran (30 mL) was then added, and the
reaction mixture was stirred for 18 h. The reaction mixture was then
washed with saturated NH4Cl(aq) (100mL), and aqueous layer was back-
extracted with EtOAc (100 mL). Combined organic layers were washed
with brine (100 mL), dried over magnesium sulfate, and concentrated
under reduced pressure, yielding 24 as a yellow oil (2.90 g, 78%).
Mixture of diketone/enol tautomers 2:1 was observed by NMR in
CDCl3 at room temperature. Diketone
1H NMR (CDCl3, δ, ppm)
4.20−4.12 (3H, m), 2.90 (2H, d, J = 7.3 Hz), 2.29 (6H, s), 1.31−1.25
(3H, m); enol 1HNMR (CDCl3, δ, ppm) 4.22−4.08 (2H, m), 3.25 (2H,
s), 2.17 (6H, s), 1.32−1.23 (3H, m).
Ethyl 2-(1,3,5-Trimethyl-1H-pyrazol-4-yl)acetate (26c). To a
solution of 24 (400 mg, 2.15 mmol) in acetic acid (3 mL) was added
methylhydrazine (125 μL, 2.37 mmol) dropwise, and reaction mixture
was stirred at room temperature for 3 h. Reaction mixture was
concentrated under reduced pressure, yielding 26c as a colorless oil (349
mg, 73%). 1HNMR (CDCl3, δ, ppm) 4.15 (2H, q, J = 7.1 Hz), 3.74 (3H,
s), 3.35 (2H, s), 2.22 (6H, s), 1.28 (3H, t, J = 7.1 Hz).
2-(1,3,5-Trimethyl-1H-pyrazol-4-yl)acetic Acid (28c). To a solution
of 26c (300 mg, 1.53 mmol) in methanol (3 mL) was added lithium
hydroxide monohydrate (642 mg, 15.3 mmol), and the mixture was
stirred at room temperature for 18 h. Reaction mixture was diluted with
water (20 mL) and acidifed with 2.0 M HCl(aq) to pH 4. Then 28c was
extracted with EtOAc (3 × 20 mL). Combined organic layers were then
dried over sodium sulfate and concentrated under reduced pressure,
yielding 28c as a pink crystalline solid (130mg, 51%). 1HNMR (CDCl3,
δ, ppm) 3.80 (3H, s), 3.41 (2H, s), 2.24 (3H, s), 2.23 (3H, s).
tert-Butyl 4-((2-(2-(2-(1,3,5-Trimethyl-1H-pyrazol-4-yl)acetyl)-
hydrazinecarbonyl)benzo[b]thiophen-3-yl)oxy)piperidine-1-carbox-
ylate (30c). 30c was prepared as in 21a replacing 2-phenylpropanoic
acid with 28c (25 mg, 0.15 mmol), yielding 30c as an orange oil (43 mg,
66%). 1H NMR (CDCl3, δ, ppm) 9.75 (1H, d, J = 6.2 Hz), 7.89−7.72
(3H, m), 7.53−7.37 (2H, m), 4.75−4.65 (1H, m), 4.12−4.06 (2H, m),
3.76 (3H, s), 3.46 (2H, s), 2.86−2.82 (2H, m), 2.26 (6H, s), 2.14−2.09
(2H, m), 1.99−1.87 (2H, m), 1.48 (9H, s).
2-(3-(Piperidin-4-yloxy)benzo[b]thiophen-2-yl)-5-((1,3,5-trimeth-
yl-1H-pyrazol-4-yl)methyl)-1,3,4-oxadiazole (34c). 34c was prepared
as in 23a replacing 21a with 30c (66 mg, 0.12 mmol) and puriﬁed by
LC−MS, yielding 34c as a yellow solid (9 mg, 17%). tR = 7.1 min; 1H
NMR (CD3OD, δ, ppm) 8.47 (1H, brs), 7.99−7.88 (2H, m), 7.61−7.45
(2H, m), 4.81 (1H, tt, J = 7.2, 4.1 Hz), 4.12 (2H, s), 3.72 (3H, s), 3.56
(2H, ddd, J = 12.1, 7.5, 4.1 Hz), 3.11 (2H, ddd, J = 12.5, 7.5, 4.1 Hz), 2.29
(3H, s), 2.22 (3H, s), 2.21−2.04 (4H, m); 13C NMR (CD3OD, δ, ppm)
170.17, 160.26, 147.99, 134.99, 139.01, 134.93, 134.27, 128.98, 126.59,
124.49, 123.45, 120.38, 109.98, 77.73, 45.42, 42.37, 36.01, 29.56, 20.79,
9.52; ESI HRMS, found 424.1801 (C22H26N5O2S, [M + H]
+, requires
424.1807).
Enzyme Inhibition Assay. All IC50 determinations were carried out
using a 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcoumarin
(CPM) ﬂuorescence assay, as described previously for HsNMT1,45
PvNMT,46 and PfNMT.21
IC50 values are the mean value of two or more determinations, and
standard deviation is within 20% of the IC50 unless otherwise speciﬁed.
Data were elaborated usingMicrosoft Oﬃce Excel 2010, and IC50 values
were determined using GraFit 7.0 (Erithacus Software Ltd., U.K.) by
nonlinear regression ﬁtting, which were then quoted as Ki as deﬁned
below.
Ki Calculations. Ki values quoted are the Ki calculated from the
experimentally determined IC50 values, the substrate concentration
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For example, 34c had an experimentally determined PfNMT IC50 of
0.017 ± 0.002 μM. The Michaelis constant (Km) was 3.64 μM and the
substrate concentration was 4.00 μM, resulting in a Ki of 0.008 μM. Km
values were calculated as described previously.45
Plasmodium falciparum Sybr Green Viability Assay. Plasmo-
dium falciparum Culture. Synchronous Plasmodium falciparum 3D7
late stage trophozoites at 33−36 h were used. Final parasitemia and
hematocrit were 0.1−0.2% and 2%, respectively. Red blood cells used for
the assay were centrifuged to remove the buﬀy coat and washed twice in
Roswell ParkMemorial Institute (RPMI)medium 1640 so that no white
blood cells were present. The culture medium contained RPMI 1640
with 5 g/L Albumax, 0.025 g/L gentamycin, and 0.292 g/L L-glutamine.
SYBR Green Assay. Sterile 96-well black tissue culture plates (Costar)
were used routinely for every assay. Drugs were diluted in culture
medium and used in duplicate wells for each dilution of 10.0, 3.333,
1.111, 0.370, 0.123, 0.041, and 0.014 μM in a ﬁnal volume of 100 μL per
well. Chloroquine was used as a standard with 10 times reduced
concentration range as above. Two sets of control were used in duplicate
wells, one set with no added drugs (positive control) and one with
uninfected red blood cells (negative control).
The plates were incubated at 37 °C for 48 h in a gas chamber ﬂushed
with 5% CO2, 5% O2, and 90% N2. After 48 h supernatants were taken
from each well and replaced with fresh drug and incubated for a further
48 h in the same manner. At the end of the 96 h incubation, 25 μL of
SYBR Green I dye (SYBR Green I nucleic acid gel stain 10000×, in
DMSO from Invitrogen) in lysis buﬀer (1 μL dye to 1 mL of lysis buﬀer)
was added to each well and stored overnight at −20 °C. The lysis buﬀer
contained Tris-HCl (20 mM, pH 8.0), EDTA (2 mM), saponin
(0.16%), and Triton X-100 (1.6% v/v).
Plates were warmed to room temperature, and ﬂuorescence intensity
was measured with a FLUOstar Omega microplate ﬂuorescence reader
(BMG Labtech). Values were expressed in relative ﬂuorescence units.
Binding of SYBR Green is speciﬁc for parasite DNA, as mature
erythrocytes lack DNA and RNA. Fluorescence intensity unit was
converted to percentage (%) of growth as follows:
= −
−
×% growth (culture under drug) (uninfected RBC)
(culture with no drug) (uninfected RBC)
100
Plasmodium falciparum [3H]Hypoxanthine Assay. This assay
was performed by Dr. Sergio Wittlin and Dr. Christian Scheurer at the
Swiss Tropical and Public Health Institute and is a modiﬁed version of
the original hypoxanthine assay published by Desjardins et al.:47
Serial drug dilutions were prepared with a multichannel pipet,
transferring 100 μL in a 2-fold serial dilution. Wells of rows A served as
controls without drug. An amount of 100 μL of infected blood
(parasitemia of 0.3%, 2.5% hematocrit) was added to all wells with a
multipipette. The control wells (A9−A12) received uninfected blood of
2.5% hematocrit. The plates were incubated in an incubation chamber at
37 °C in an atmosphere containing 93% N2, 4% CO2, 3% O2. After 48 h,
an amount of 50 μL of [3H]hypoxanthine (=0.5 μCi) solution was added
to each well of the plate. The plates were incubated for another 24 h. The
plates were then harvested with a Betaplate cell harvester (Wallac,
Zurich, Switzerland). The dried ﬁlters were inserted into a plastic foil
with 10 mL of scintillation ﬂuid and counted in a Betaplate liquid
scintillation counter (Wallac, Zurich, Switzerland). The results were
recorded as counts per minute (cpm) per well at each drug
concentration.
Data were analyzed using a graphic program (e.g., Excel) and
expressed as percentage of the untreated controls. The 50% inhibitory
concentration (IC50) value was evaluated by logit regression analysis.
Plasmodium berghei Liver Stage Assay. This assay is a slightly
modiﬁed version of the assay previously described:5
HepG2-A16-CD81EGFP cells stably transformed to express a GFP-
CD81 fusion protein were cultured at 37 °C in 5% CO2 in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS, 0.29
mg/mL glutamine, 100 units of penicillin, and 100 μg/mL streptomycin.
The cells were seeded 24 h prior to infection into 1536-well plates at
3000 cells/well. The cells were pretreated for 12 h with the drug in a 12-
point dilution series, and the cells were then infected with freshly
dissected P. berghei sporozoites expressing luciferase (1000 sporozoites/
well). After 48 h of incubation, the viability of P. berghei exoerythrocytic
forms (EEF) was measured by bioluminescence. IC50 values were
obtained using the measured bioluminescence intensity and a nonlinear
variable slope four-parameter regression curve ﬁtting model in Prism 6
(GraphPad Software Inc.).
HepG2 Toxicity Assay. Measurement of the ability of 34c to kill
human cells (HepG2, human hepatocellular carcinoma) was performed
using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS), cell viability assay,
modiﬁed from the Promega Corporation Technical Bulletin No. TB169.
The cells were cultured inDulbecco’s modiﬁed Eagle medium (DMEM)
plus 10% fetal bovine serum (FBS) plus 1% penicillin/streptomycin,
incubated at 37 °C in humidiﬁed atmosphere with 5% CO2.
Then 200 μL of mediumwas added to wells 2−7 of a 12-well reservoir
per replicate, along with 598 μL of medium in well 1. Compound was
dissolved in DMSO at a top concentration of 50 mM, and 1.8 μL of this
stock was added to column 1. Well 1 was mixed thoroughly with a 1 mL
pipet, and 200 μL was transferred to well 2 and mixed thoroughly. This
was repeated until well 7. Furthermore, a puromycin control was
prepared by diluting 3 μL of puromycin stock (1 mg/mL) in 1497 μL of
medium.
Cells were added to a 96-well plate at a concentration of 5000 cells per
well (50 μL), excluding the exterior wells. To wells B2−G2 and B11−
G11 is added 100 μL of 0.2% DMSO/medium (positive control wells).
To wells B3−G3 was added 100 μL of puromycin/medium (negative
control wells). To wells B4−B10, C4−C10, and D4−D10 was added
100 μL of each of the seven drug dilutions. This was repeated with a
second compound if required in wells E4−E10, F4−F10, and G4−G10.
The plate was placed in an incubator at 37 °C and cell growth/
morphology inspected at 24, 48, and 72 h.
At 72 h, 20 μL ofMTS/PMS solution (1.9 mg/mLMTS, 43.8 μg/mL
PMS) was added to each assay well, and the plate returned to the
incubator for 4 h. Fluorescence was then read at 490 nm on a
SpectraMax M2e microplate reader from Molecular Devices. Data were
elaborated using Microsoft Oﬃce Excel 2011, and LD50 values were
determined using GraFit 7.0 (Erithacus Software Ltd., U.K.) by
nonlinear regression ﬁtting.
Crystallography. Crystals of ternary complexes of PvNMT, a
nonhydrolyzable myristoyl-CoA analogue (NHM),48 and the inhibitors
20b and 34a were prepared as described previously.21
X-ray diﬀraction data were collected on synchrotron beamlines at the
Diamond Light Source, Harwell, U.K., and processed using XDS49 and
SCALA50 implemented within xia2.51
Model reﬁnement was by maximum likelihood methods imple-
mented in REFMAC52 using the protein chains of 4A95.pdb46 as a
starting model interspersed with cycles of model building and
adjustment using COOT.53 A summary of data collection and
reﬁnement statistics is in Supporting Information.
■ ASSOCIATED CONTENT
*S Supporting Information
Experimental procedures and characterization of all intermedi-
ates and target compounds, full biological results, and X-ray
crystallographic collection data and reﬁnement statistics. This
material is available free of charge via the Internet at http://pubs.
acs.org.
Accession Codes
The coordinates and structure factor ﬁles have been deposited in
the Protein Data Bank under the accession codes 4CAE
(PvNMT-NHM-20b) and 4CAF (PvNMT-NHM-34a).
■ AUTHOR INFORMATION
Corresponding Author
*Phone: +44 (0) 20 7594 3752. E-mail: e.tate@imperial.ac.uk.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm500066b | J. Med. Chem. 2014, 57, 2773−27882786
Present Address
⊥R.J.L.: Liverpool John Moores University, Egerton Court, 2
Rodney Street, Liverpool L1 2UA, U.K.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The authors are grateful to Andrew Bell, Jennie Hutton, and
Zhiyong Yu for valuable discussions. We thank Sergio Wittlin
and Christian Scheurer for performing assays on NF54, K1, and
Dd2 Pf cell lines, and Elizabeth A. Winzeler and colleagues for
enabling access to the liver stage assay. We also thank the
Medicines for Malaria Venture (MMV) for funding Elizabeth A.
Winzeler to support liver assays at University of California San
Diego, and Sergio Wittlin to support cell-line testing at Swiss
TPH.We thankWilliamHeal and Zhiyong Yu for performing the
HepG2 toxicity assay. We thank Munira Grainger for providing
the parasites used in the in vitro assay, and Barbara Clough for
performing the assay. We acknowledge the Diamond Light
Source, Harwell, U.K., for the provision of data collection
facilities and Shirley Roberts for expert crystal handling. This
work was supported by the Engineering and Physical Sciences
Research Council (Doctoral Prize Fellowship) and Medical
Research Council (MRC Grants 0900278 and U117532067).
■ ABBREVIATIONS USED
nd, not determined; Pb, Plasmodium berghei; Pv, Plasmodium
vivax; Pf, Plasmodium falciparum; Ld, Leishmania donovani;
NMT, N-myristoyltransferase; Hs, Homo sapiens; LE, ligand
eﬃciency; LELP, cLogP/LE;MTS, 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt; DMEM, Dulbecco’s modiﬁed Eagle medium;
FBS, fetal bovine serum; PMS, phenazine methosulfate
■ REFERENCES
(1) Murray, C. J. L.; Rosenfeld, L. C.; Lim, S. S.; Andrews, K. G.;
Foreman, K. J.; Haring, D.; Fullman, N.; Naghavi, M.; Lozano, R.;
Lopez, A. D. Global malaria mortality between 1980 and 2010: a
systematic analysis. Lancet 2012, 379, 413−431.
(2) World Malaria Report 2011. http://www.who.int/malaria/world_
malaria_report_2011/en/ (accessed Jan 18, 2012).
(3) Singh, B.; Sung, L. K.; Matusop, A.; Radhakrishnan, A.; Shamsul, S.
S. G.; Cox-Singh, J.; Thomas, A.; Conway, D. J. A large focus of naturally
acquired Plasmodium knowlesi infections in human beings. Lancet 2004,
363, 1017−1024.
(4) Delves, M.; Plouffe, D.; Scheurer, C.; Meister, S.; Wittlin, S.;
Winzeler, E. A.; Sinden, R. E.; Leroy, D. The activities of current
antimalarial drugs on the life cycle stages of Plasmodium: a comparative
study with human and rodent parasites. PLoS Med. 2012, 9, e1001169.
(5) Meister, S.; Plouffe, D. M.; Kuhen, K. L.; Bonamy, G. M. C.; Wu,
T.; Barnes, S. W.; Bopp, S. E.; Borboa, R.; Bright, A. T.; Che, J.; Cohen,
S.; Dharia, N. V.; Gagaring, K.; Gettayacamin, M.; Gordon, P.; Groessl,
T.; Kato, N.; Lee, M. C. S.; McNamara, C. W.; Fidock, D. A.; Nagle, A.;
Nam, T.-g.; Richmond, W.; Roland, J.; Rottmann, M.; Zhou, B.;
Froissard, P.; Glynne, R. J.; Mazier, D.; Sattabongkot, J.; Schultz, P. G.;
Tuntland, T.; Walker, J. R.; Zhou, Y.; Chatterjee, A.; Diagana, T. T.;
Winzeler, E. A. Imaging of Plasmodium liver stages to drive next-
generation antimalarial drug discovery. Science 2011, 334, 1372−1377.
(6) Derbyshire, E. R.; Mota, M. M.; Clardy, J. The next opportunity in
anti-malaria drug discovery: the liver stage. PLoS Pathog. 2011, 7,
e1002178.
(7) Fidock, D. A.; Nomura, T.; Talley, A. K.; Cooper, R. A.; Dzekunov,
S. M.; Ferdig, M. T.; Ursos, L. M. B.; bir Singh Sidhu, A.; Naude,́ B.;
Deitsch, K. W.; Su, X.-z.; Wootton, J. C.; Roepe, P. D.; Wellems, T. E.
Mutations in the P. falciparum digestive vacuole transmembrane protein
PfCRT and evidence for their role in chloroquine resistance. Mol. Cell
2000, 6, 861−871.
(8) Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.;
Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.;
Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S.
S.; Yeung, S.; Singhasivanon, P.; Day, N. P. J.; Lindegardh, N.; Socheat,
D.; White, N. J. Artemisinin resistance in Plasmodium falciparummalaria.
N. Engl. J. Med. 2009, 361, 455−467.
(9) Phyo, A. P.; Nkhoma, S.; Stepniewska, K.; Ashley, E. A.; Nair, S.;
McGready, R.; ler Moo, C.; Al-Saai, S.; Dondorp, A. M.; Lwin, K. M.;
Singhasivanon, P.; Day, N. P.; White, N. J.; Anderson, T. J.; Nosten, F.
Emergence of artemisinin-resistant malaria on the western border of
Thailand: a longitudinal study. Lancet 2012, 379, 1960−1966.
(10) Medicines for Malaria Venture. Interactive R&D Portfolio.
http://www.mmv.org/research-development/rd-portfolio (accessed
Dec 8, 2013).
(11) Wright, M. H.; Heal, W. P.; Mann, D. J.; Tate, E. W. Protein
myristoylation in health and disease. J. Chem. Biol. 2010, 3, 19−35.
(12) Tull, D.; Heng, J.; Gooley, P. R.; Naderer, T.; McConville, M. J.
Acylation-dependent and independent membrane targeting and distinct
functions of small myristoylated proteins (SMPs) in Leishmania major.
Int. J. Parasitol. 2012, 42, 239−247.
(13) Patwardhan, P.; Resh, M. D. Myristoylation and membrane
binding regulate c-Src stability and kinase activity. Mol. Cell. Biol. 2010,
30, 4094−4107.
(14) Resh, M. D. Targeting protein lipidation in disease. Trends Mol.
Med. 2012, 18, 206−214.
(15) Zhao, H.; Sun, J.; Deschamps, A.M.; Kim, G.; Liu, C.; Murphy, E.;
Levine, R. L. Myristoylated methionine sulfoxide reductase A protects
the heart from ischemia−reperfusion injury. Am. J. Physiol.: Heart Circ.
Physiol. 2011, 301, H1513−H1518.
(16) Poulin, B.; Patzewitz, E. M.; Brady, D.; Silvie, O.; Wright, M. H.;
Ferguson, D. J.; Wall, R. J.; Whipple, S.; Guttery, D. S.; Tate, E. W.;
Wickstead, B.; Holder, A. A.; Tewari, R. Unique apicomplexan IMC sub-
compartment proteins are early markers for apical polarity in the malaria
parasite. Biol. Open 2013, 2, 1160−1170.
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